Visilizumab

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NameVisilizumab
Drug Alias Name维西珠单抗Anti-CD3 monoclonal antibody humanised - Protein Design LabsSMART anti-CD3 MAbHuM-291Nuvion +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT cell surface glycoprotein CD3 inhibitorsImmunosuppressants
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsGraft vs Host DiseaseCrohn DiseaseColitis, Ulcerative +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[18] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPdl Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesStanford UniversityH Lee Moffitt Cancer Center & Research Institute +[5] 
Active IndicationsN/A
Inactive IndicationsGraft vs Host DiseaseCrohn DiseaseColitis, Ulcerative +[5] 

Other Information

ATC CodeN/A
Related LinksN/A